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Background: While	 treatment	 for	 atopic	 rhinitis	 is	 aimed	mostly	 to	 relieve	 symp‐
toms,	only	allergen‐specific	 immunotherapy	(AIT)	 is	targeted	to	modify	the	natural	
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1  | INTRODUC TION
Rhinoconjunctivitis	and	other	IgE‐mediated	allergies	are	an	increas‐
ing	 disease	 burden	 globally.1	 Most	 therapies	 for	 allergies	 are	 di‐
rected	at	relieving	symptoms,	but	allergen‐specific	immunotherapy	
(AIT)	 is	 the	only	current	 therapy	 that	modifies	 the	natural	course	
of	 allergic	 diseases.	 Subcutaneous	 immunotherapy	 (SCIT)	 and	
sublingual	 immunotherapy	 (SLIT)	 are	both	proven	effective	 treat‐





immune	 responses,	 with	 an	 impact	 on	 the	 number	 and	 function	
of	 mast	 cells,	 basophils,	 antigen‐presenting	 cells,	 T	 cells,	 and	 B	
cells.10,11
Allergic	 patients	 manifest	 sensitization	 by	 means	 of	 allergen‐
specific	 IgE	 bound	 to	 effector	 cells,	 particularly	 mast	 cells	 and	
basophils.12	 The	 underlying	mechanism	 is	 thought	 to	 be	 a	 shifted	
T‐cell	balance	toward	a	T	helper	2	(Th2)	phenotype,	and	these	cells	
produce	 interleukin	 (IL)‐4	 and	 IL‐13	 that	 direct	 allergen‐specific	 B	





























other	 studies	 detected	 no	 systemic	 alterations	 with	 regard	 to	
K E Y W O R D S
B	cells,	flow	cytometry,	IgE,	immunotherapy	and	tolerance	induction,	Rhinitis





     |  3HEERINGA Et Al.
allergen‐specific	 lymphoproliferation,	 cytokine	 secretion,	 or	 Ig	
serum	levels.36,37
IgG2	 and	 IgG4	 heavy	 chain	 constant	 regions	 are	 encoded	 by	





in	variable	 regions	of	 IgG2	 and	 IgG4	 transcripts,	 it	has	been	sug‐
gested	that	B	cells	expressing	these	transcripts	have	spent	more	
time	 in	 the	germinal	 center	 response.39	 In	addition,	 the	majority	
of	 IgG2‐	 and	 IgG4‐expressing	B	 cells	 co‐express	CD27,	 and	 their	
frequencies	 increase	with	 age.40,41	 Hence,	 it	 appears	 that	 these	
Ig	class	switches	occur	following	repeated	exposure	to	the	same	
antigen.
Since	AIT	has	been	 shown	 to	have	 long‐lasting	beneficial	 ef‐
fects,	 it	 is	 important	 to	 determine	 whether	 this	 is	 the	 result	 of	
changes	in	immunological	memory.	We	here	address	this	question	
in	our	cohort	of	patients	with	moderate‐to‐severe	seasonal	aller‐
gic	 rhinitis,	 studied	 longitudinally	 before,	 during,	 and	 after	 SLIT	
for	grass	pollen	allergy.42	As	published	previously,42,43	SLIT	in	our	
















1—1	tablet	100	 IR	 (index	of	 reactivity);	day	2—2	tablets	100	 IR;	and	
day	3	to	day	120—1	daily	tablet	300	IR.	Blood	samples	were	collected	





Participants	 were	 recruited	 from	 The	 Alfred	 Hospital	 Allergy	
Clinic,	 Melbourne,	 Victoria,	 Australia.	 All	 had	 well‐character‐
ized	moderate‐to‐severe	 seasonal	 allergic	 rhinitis	 (plus	or	minus	
asthma)	 due	 to	 RGP	 allergy	 with	 positive	 serum	 RGP‐specific	
IgE	 (≥0.35	 kU/L;	 ImmunoCAP,	 Phadia).	 Exclusion	 criteria	were	 a	
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co‐existing	 immunodeficiency,	 previous	 immunotherapy	 within	
the	last	5	years,	ongoing	immunotherapy	with	other	allergens,	and	
treatment	 with	 continuous	 oral	 corticosteroids	 and/or	 β‐block‐
ers.	The	use	of	usual	medications	for	allergic	rhinitis	was	permit‐
ted,	 including	 antihistamines	 and	 topical	 corticosteroids.	 Alfred	
Hospital	 Research	 and	 Ethics	 Committee	 approval	 and	 written	
informed	 consent	 from	 each	 participant	were	 obtained	 prior	 to	
inclusion	 (project	 number	514/13).	 Twenty‐nine	participants	 (12	
males)	were	recruited	for	treatment,	with	a	mean	age	of	35	years	
(range	18‐59	year)	and	mean	serum	RGP‐specific	IgE	of	52	kU/L.	
Five	withdrew	after	 the	 first	 (baseline)	 time	point	 (n	=	4	 tongue	
swelling,	upset	stomach;	n	=	1	failed	to	attend)	leaving	24	partici‐
pants	who	commenced	SLIT	(Table	S1).	At	subsequent	time	points,	
three	 participants	 failed	 to	 attend	 after	 4	months	 of	 treatment	
and	a	further	seven	participants	were	excluded	after	1	year	(n	=	2	
opted	to	receive	SCIT,	n	=	2	opted	to	receive	sublingual	drops,	and	
n	 =	 3	withdrew).	 Blood	 samples	 for	 serum	 and	 flow	 cytometric	
analysis	were	 obtained	 from	 n	 =	 24	 patients	 in	May	 2014	 prior	
to	starting	SLIT,	n	=	24	in	September	2014,	n	=	21	in	May	2015,	
n	=	14	 in	May	2016,	and	n	=	14	 in	May	2017.	Details	on	sample	




2.3 | Clinical parameters of allergic rhinitis
Allergic	 rhinitis	 symptoms	 during	 the	 peak	 RGP	 season	 were	 re‐
corded	by	the	participants	using	a	visual	analog	score	 (VAS;	scale,	





2.4 | Quantification of serum total IgE and allergen‐





Greer),	 blocked	 with	 2%	 bovine	 serum	 albumin	 in	 PBS	 (Sigma‐
Aldrich),	 and	 incubated	 with	 serial	 dilutions	 of	 serum	 samples.	
Separate	wells	were	coated	with	serial	dilutions	of	purified	human	
IgG2	 (Sigma‐Aldrich,	 #I5404)	 to	 generate	 a	 standard	 curve	 for	
quantification	of	IgG2	in	serum	samples.	Bound	IgG2	was	detected	
using	 biotinylated	 anti‐hIgG2	 (clone	 HP6002;	 Thermo	 Scientific)	
followed	 by	 Pierce	 High	 Sensitivity	 Streptavidin‐HRP	 (Thermo	
Scientific).	 ELISA	was	 developed	 using	 TMB	 (Thermo	 Scientific),	
and	 the	 reaction	 stopped	 with	 1	 mol/L	 HCl.	 Absorbance	 (OD	
450	 nm)	 was	 measured	 using	 a	 FLUOstar	 Optima	 plate	 reader	
(BMG	Labtech).
2.5 | In vitro RGP stimulation of PBMC, Treg 
staining, and measurement of cytokines










The	 levels	 of	 IFN‐γ,	 IL‐5,	 IL‐10,	 and	 IL‐13	 in	 7‐day	 culture	 su‐
pernatants	 were	 determined	 using	 a	 Luminex	 human	 premixed	
multi‐analyte	 kit	 (R&D	 Systems	 Inc)	 according	 to	 the	manufactur‐
er's	instructions.	Due	to	changes	in	IL‐5	production	observed	after	




2.6 | B‐cell subset analysis by flow cytometry
One	million	thawed	PBMC	were	incubated	with	11‐color	antibody	
cocktails	against	B‐cell	markers	for	15	minutes	at	room	tempera‐
ture	 in	100	µL	 total	volume	 (Table	S3).	Flow	cytometric	analyses	
were	 performed	 on	 a	 4‐laser	 LSRFortessa	 (BD	 Biosciences),	 and	
data	were	analyzed	using	FACSDiva	V8.0	(BD	Biosciences).	B‐cell	
subsets	were	defined	as	described	previously.41,45,46	Briefly,	within	
the	 CD19+	 B‐cell	 population,	 the	 proportions	 were	 determined	
of	 plasmablasts	 (CD27+CD38high),	 transitional	 (CD27−CD38high),	
naive	 mature	 (CD27−IgM+IgD+),	 natural	 effector	 memory	 B	 cells	
(CD27+IgM+IgD+),	and	IgM‐only	memory	B	cells	 (CD27+IgM+IgD–).	
Furthermore,	 we	 analyzed	 Ig	 switched	 CD27−CD38dim and 
CD27+CD38dim	memory	B	cells	expressing	IgA,	IgE,	IgG,	or	each	of	
the	4	IgG	subclasses.
2.7 | Molecular analysis of Ig gene rearrangements




MA).	 Rearranged	 IgG	 transcripts	were	 amplified	 in	 a	multiplex	 PCR	
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mutations	were	determined	within	the	entire	IGHV	gene	(FR1‐CDR1‐













lyzed	 with	 the	 chi‐squared	 test.	 Statistical	 analysis	 was	 performed	
using	GraphPad	Prism	software,	version	7.01	(GraphPad	Software).
3  | RESULTS
3.1 | SLIT reduces symptoms of allergic rhinitis
To	 study	 the	 clinical	 effects	 of	 SLIT,	 we	 assessed	 the	 severity	 of	
symptoms	for	allergic	rhinitis	using	a	VAS.	Before	the	start	of	treat‐
ment,	participants	reported	a	median	VAS	of	80	mm	for	 the	2013	
pollen	 season	 (Figure	 1B).	 In	 the	 first	 pollen	 season	 after	 com‐





The	 level	 of	 RGP	 sensitization	 was	 monitored	 by	 skin	 prick	
tests	(SPT)	with	wheal	diameters	(mm)	positively	correlating	with	
symptoms	of	 allergic	disease.48	 SLIT	 significantly	decreased	SPT	
wheal	diameter	in	response	to	SPT	with	RGP	extract	within	1	year	
of	 commencing	 therapy	 (Figure	 1C).	 Wheal	 size	 remained	 low	
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3.2 | Induction of RGP‐specific Treg and IL‐10 
production following SLIT







tified	 IL‐5,	 IL‐10,	 IL‐13,	and	 IFN‐γ	production	 from	RGP‐stimulated	
PBMC.	 After	 3	 years	 of	 SLIT,	 T	 cells	 produced	 significantly	more	
IL‐10	 and	 IFN‐γ	 and	 significantly	 less	 IL‐5	 and	 IL‐13	 (Figure	 2B‐E).	
SLIT	 did	 not	 alter	 the	 PBMC	 cytokine	 response	 to	 tetanus	 toxoid	
(Figure	S2).	Taken	together,	the	data	from	our	study	suggest	SLIT	en‐
hances	Treg	response	to	allergen	within	4	months	without	impacting	
the	 Treg	 response	 to	 other	 antigens.	 Furthermore,	 SLIT	may	 alter	
the	Th1/Th2	cytokine	profile	away	from	pro‐allergic	Th2	cytokines	
toward	a	regulatory	and	Th1‐biased	response.
3.3 | Increased IgG4 serum levels and IgG4
+ memory 
B‐cell frequencies after 4 months SLIT
To	 study	 the	 short‐term	 effects	 of	 SLIT	 on	 the	 immune	 system,	
we	analyzed	serum	Ig	levels	and	B‐cell	subsets	before	and	directly	
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after	 the	 first	 4	 months	 of	 therapy.	 The	 gating	 strategies	 for	
flow	cytometric	detection	of	memory	B	cells	expressing	the	four	
IgG	 subclasses	 are	 shown	 in	 Figure	 3A.	We	 observed	 that	 after	





crease	 in	 the	 frequency	of	 IgG+	memory	B	cells	 (CD19+CD38dim)	
expressing	 IgG4	 (Figure	 3C).	 The	 increase	 in	 the	 IgG4
+ memory 
B‐cell	 frequencies	was	 not	 directly	 correlated	with	 the	 increase	








naive	 mature,	 memory,	 and	 plasmablasts,	 remained	 unchanged	
after	4	months	of	SLIT	(Figure	S3).	Thus,	4	months	SLIT	quite	spe‐
cifically	affected	allergen‐specific	 IgG4	 serum	 levels	and	the	fre‐
quencies	of	IgG4‐expressing	memory	B	cells.
3.4 | SLIT has persistent long‐term effects on 









memory	 B	 cells	 were	 unchanged	 by	 SLIT,	 while	 IgG2
+	 memory	 B	
cells	 were	 significantly	 increased	 3	 years	 after	 commencing	 SLIT	
(Figure	 4B).	 Frequencies	 of	 IgG4
+	 memory	 B	 cells	 were	 increased	
2	years	after	commencing	SLIT.
3.5 | Molecular analysis of Ig gene rearrangements
Given	that	SLIT	increased	IgG2	and	IgG4	antibodies	and	memory	B‐
cell	 proportions,	we	 investigated	whether	 these	 changes	were	 re‐













+	B‐cell	proportions	and	skewing	toward	unique	 IgG2 and 
IgG4	transcripts.
4  | DISCUSSION
We	 here	 report	 that	 SLIT	 for	 grass	 pollen	 allergy	 not	 only	 has	
long‐term	 beneficial	 clinical	 effects,	 but	 also	 results	 in	 sustained	









and	co‐seasonal	 course	starting	4	months	prior	 to	 the	hay	 fever	
season,	 confirmed	 by	meta‐analyses	 as	 clinically	 effective.2	 Yet,	
long‐term	 treatment	 regimens	 are	 costly	 and	 discourage	 treat‐
ment	adherence.51	As	patients	are	exposed	to	grass	pollens	during	
the	spring	season,	we	reasoned	that	a	4	months	preseasonal	treat‐
ment	 regimen	 would	 avoid	 the	 risk	 of	 adding	 to	 excessive	 and	
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after	 the	 second	 or	 third	 treatment	 year	 as	 observed	 for	 serum	
RGP‐specific	 IgG2	 levels,	 or	 continuing	 to	 rise	 after	 consecutive	
treatment	as	 for	 serum	RGP‐specific	 IgG4	 levels,	 supports	 these	
premises.
In	particular,	we	observed	a	marked	 increase	 in	RGP‐specific	
IgG.	 Previously,	 allergen‐specific	 immunotherapy,	 either	 SCIT	 or	
SLIT,	 has	 already	 been	 demonstrated	 to	 result	 in	 increased	 al‐
lergen‐specific	 IgG4	 serum	 levels.
53,54	 Increased	 allergen‐spe‐
cific	IgG4	has	been	postulated	as	one	of	the	explanations	for	the	
beneficial	 effects	 of	 immunotherapy	 and	 has	 been	 observed	 as	
a	 natural	 effect	 in	 beekeepers	 exposed	 to	 bee	 venom	 for	 pro‐
longed	 periods,55	 yet	 the	 exact	 desensitizing	 effect	 of	 specific	
IgG4	 in	 immunotherapy	 remains	 unclear.	 Allergen‐specific	 IgG4 
can	 competitively	 inhibit	 IgE	 from	 binding	 to	 allergens	 and	may	
subsequently	reduce	allergic	responses	by	preventing	FcεR‐medi‐
ated	activation	of	granulocytes.56	Furthermore,	IgG4	antibody	has	
been	 proposed	 to	 inhibit	 inflammatory	 responses	 by	 preventing	
C1q	complement	activation	and	binding	to	the	inhibitory	receptor	
FcγRIIb	(CD32b).57,58
SLIT	 also	 increased	 RGP‐specific	 IgG2	 after	 three	 consecutive	




erentially	 induced	 an	 IgG2	 response	 not	 seen	 from	 environmental	
exposure	through	the	airway.
The	 immune	mechanisms	 by	which	 allergen‐specific	 IgG2 may 








able	 to	 assess	 these.	However,	we	 did	 assess	 the	more	 immature	












of	 IgE+	memory	B‐cell	 subsets.	The	 latter	observation	 can	explain	
the	absence	of	a	decline	 in	 IgE	serum	 levels	as	also	demonstrated	















memory	 B	 cells	 upon	 repeated	 exposure	 to	 allergen.	 Sequential	
Ig	class	switching	can	only	occur	5’–3’	along	the	IGH	locus,	which	
is	arranged	in	the	following	order:	IgG3	>	IgG1	>	IgG2	>	IgG4	>	Ig
E	>	 IgA	 (Figure	5A).	As	such,	 IgG1













mined	whether	allergen‐specific	 IgG2	and	 IgG4	are	 indispensable	
for	 generating	 clinical	 benefit	 by	 SLIT	 in	 lieu	 of	 T	 cell–mediated	
tolerance.
In	 line	with	previous	 reports,	we	observed	 that	proliferation	
of	Treg	from	patients	after	SLIT	was	 increased	 in	response	to	 in	
vitro	stimulation	with	RGP.	Previous	studies	have	observed	new	
generation	of	 allergen‐specific	 Treg,	 as	well	 as	 clonal	 expansion	
of	allergen‐specific	Treg	in	response	to	AIT.56,64	Furthermore,	we	
observed	 that	SLIT	 increased	 IL‐10	production	 from	RGP‐stimu‐




inantly	 secreted	 by	 Treg.	 Our	 data	 are	 consistent	 with	 SLIT‐in‐
duced	proliferation	of	 allergen‐specific	Treg,	whereby	 increased	
IL‐10	 production	 induces	 Ig	 class	 switching	 of	 allergen‐specific	







sociated	with	 increased	 frequency	of	 IgG4
+	memory	B	 cells	 and	 a	
beneficial	shift	in	the	IgG4
+/IgE+	memory	B‐cell	ratio,	reflecting	the	
increased	 IgG4/IgE	 antibody	 fraction	 in	 serum	 and	 resultant	 clini‐
cally	favorable	outcome.	Moreover,	to	our	knowledge,	our	study	is	
the	first	to	demonstrate	increases	in	memory	B	cells	expressing	IgG2 
10  |     HEERINGA Et Al.
or	 IgG4	 following	 allergen	 immunotherapy.	As	 IgG2	 and	 IgG4 have 
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